A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents (Q48246762)

9 February 2018

title

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents (English)

1 reference

9 February 2018

main subject

obesity

0 references

author

Christoffer Clemmensen

1 reference

9 February 2018

Jonathan Campbell

1 reference

9 February 2018

Matthias Tschöp

object named as

Matthias H Tschöp

1 reference

9 February 2018

Katrin Fischer

0 references

Sabine Uhles

0 references

Paul T Pfluger

0 references

Daniel J Drucker

1 reference

9 February 2018

Timo D. Müller

object named as

Timo D Müller

1 reference

9 February 2018

author name string

Brian Finan

1 reference

9 February 2018

Bin Yang

1 reference

9 February 2018

Nickki Ottaway

1 reference

9 February 2018

David L Smiley

1 reference

9 February 2018

Tao Ma

1 reference

9 February 2018

Joe Chabenne

1 reference

9 February 2018

Lianshan Zhang

1 reference

9 February 2018

Kirk M Habegger

1 reference

9 February 2018

Darleen Sandoval

1 reference

9 February 2018

Randy J Seeley

1 reference

9 February 2018

Konrad Bleicher

1 reference

9 February 2018

William Riboulet

1 reference

9 February 2018

Jürgen Funk

1 reference

9 February 2018

Cornelia Hertel

1 reference

9 February 2018

Sara Belli

1 reference

9 February 2018

Elena Sebokova

1 reference

9 February 2018

Karin Conde-Knape

1 reference

9 February 2018

Anish Konkar

1 reference

9 February 2018

Vasily Gelfanov

1 reference

9 February 2018

Diego Perez-Tilve

1 reference

9 February 2018

Richard D DiMarchi

1 reference

9 February 2018

language of work or name

English

0 references

publication date

8 December 2014

1 reference

9 February 2018

published in

Nature Medicine

1 reference

9 February 2018

volume

1 reference

9 February 2018

issue

1 reference

9 February 2018

page(s)

27-36

1 reference

9 February 2018

A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1.

cites work

1 reference

12 December 2020

Peptide lipidation stabilizes structure to enhance biological function

1 reference

12 December 2020

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

1 reference

12 December 2020

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

1 reference

12 December 2020

The unrelenting fall of the pharmacological treatment of obesity

1 reference

12 December 2020

Oxyntomodulin increases intrinsic heart rate through the glucagon receptor

1 reference

12 December 2020

A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice

1 reference

12 December 2020

Pharmacology, physiology, and mechanisms of incretin hormone action

1 reference

12 December 2020

Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21

1 reference

12 December 2020

Anti-obesity drugs: past, present and future

1 reference

12 December 2020

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice

1 reference

12 December 2020

Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice

1 reference

12 December 2020

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice

1 reference

12 December 2020

Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.

1 reference

12 December 2020

Targeted estrogen delivery reverses the metabolic syndrome

1 reference

12 December 2020

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

1 reference

12 December 2020

Fibroblast growth factor 21 mediates specific glucagon actions

1 reference

12 December 2020

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

1 reference

12 December 2020

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

1 reference

12 December 2020

A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties

1 reference

12 December 2020

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

1 reference

12 December 2020

Optimization of the native glucagon sequence for medicinal purposes

1 reference

12 December 2020

GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet

1 reference

12 December 2020

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice

1 reference

12 December 2020

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

1 reference

12 December 2020

Fat: an evolving issue

1 reference

12 December 2020

GLP-1 and energy balance: an integrated model of short-term and long-term control

1 reference

12 December 2020

A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.

1 reference

12 December 2020

The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice

1 reference

12 December 2020

Gastrointestinal hormones and bariatric surgery-induced weight loss

1 reference

12 December 2020

Functional GIP receptors are present on adipocytes

1 reference

12 December 2020

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

1 reference

12 December 2020

The metabolic actions of glucagon revisited

1 reference

12 December 2020

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.

1 reference

12 December 2020

Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NM.3761

1 reference

9 February 2018

Dimensions Publication ID

1005438533

0 references

1 reference

9 February 2018